Experimental Pill Daraxonrasib Nearly Doubles Survival in Advanced Pancreatic Cancer

For decades, pancreatic cancer has remained one of the cruelest diagnoses in oncology. The disease arrives quietly, often undetected until it has already spread through the body. By the time symptoms emerge—abdominal pain, unexplained weight loss, yellowing skin, exhaustion—the cancer has usually metastasized beyond the reach of surgery. The tumors themselves are relentless, resistant to the chemotherapy regimens that work against other malignancies. Median survival for advanced pancreatic cancer has hovered around six to seven months, a statistic that has barely budged for years despite incremental improvements in other cancer treatments.

Now, researchers are reporting something different. An experimental oral medication called daraxonrasib has nearly doubled survival time in patients whose pancreatic cancer had already resisted standard treatment. The findings, presented at the American Society of Clinical Oncology meeting in Chicago and published in the New England Journal of Medicine, represent what specialists are calling a major shift in how this disease might be managed.

The drug works by targeting a specific mutation—a broken version of a protein called KRAS—that drives tumor growth in more than 90 percent of pancreatic cancer cases. Scientists have been chasing this target for decades. Previous attempts to block it produced disappointing results. Daraxonrasib, taken as a daily pill, appears to finally accomplish what earlier treatments could not: it slows the cancer's growth and extends life.

The clinical trial enrolled approximately 500 patients with metastatic pancreatic cancer whose disease had progressed despite prior chemotherapy. Half received daraxonrasib; the other half received additional chemotherapy. The difference was striking. Patients on the new drug survived a median of 13.2 months, compared to 6.7 months for those who continued with chemotherapy. Beyond the survival numbers, researchers noted that patients taking daraxonrasib experienced less severe side effects, less pain, and in many cases, visible shrinkage of their tumors. The quality-of-life improvements were substantial enough that oncologists involved in the study began describing the drug as a potential new standard of care.

Dr. Zev Wainberg from UCLA, one of the lead researchers, called the results "a very large step forward." Dr. Brian Wolpin from Dana-Farber Cancer Institute echoed the sentiment, suggesting the drug could reshape treatment protocols for patients in this category. Researchers are now investigating whether daraxonrasib might help patients earlier in their disease course, even before surgery becomes an option.

The treatment is not without drawbacks. Some patients developed skin rashes and mouth sores. Doctors emphasize that daraxonrasib is not a cure—it extends life and improves its quality, but the cancer ultimately progresses in most patients. The long-term safety profile remains under study as researchers continue monitoring trial participants.

For the pancreatic cancer community, the significance lies not in perfection but in movement. For years, oncologists have had few meaningful options to offer patients whose tumors had already outsmarted conventional therapy. Daraxonrasib represents the first real advance against the KRAS mutation that has eluded treatment for so long. If the drug continues to perform as the trial suggests, thousands of patients diagnosed with advanced pancreatic cancer each year may gain not just months of additional life, but months with less suffering and greater hope.